Cassava Sciences, Inc. Common Stock FLNA · Stock Open Cassava Sciences, Inc. Common Stock in new tab
Analyst price targets
Recent rating changes, newest first
Cassava Sciences, Inc. Common Stock Analysis (FLNA)
Is Cassava Sciences, Inc. Common Stock a good investment? Cassava Sciences, Inc. Common Stock (FLNA) is currently trading at 0.5780 USD. Market analysts have a consensus price target of 6.50 USD. This suggests a potential upside from current levels.
Earnings Schedule: Cassava Sciences, Inc. Common Stock is expected to release its next earnings report on Nov. 5, 2026.
Investor FAQ
Does Cassava Sciences, Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Cassava Sciences, Inc. Common Stock?
Cassava Sciences, Inc. Common Stock is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -0.87.
Company Profile
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
| Year | Total Dividends |
|---|---|
| ▸2012 |
5.25 USD
|
| Dec. 13, 2012 | 5.2500 |
| ▸2010 |
14.00 USD
|
| Dec. 13, 2010 | 14.0000 |
Community Discussion